While limitations have been attributed to the blood brain barrier, GBM tumor heterogeneity, and possible activation of alternative pathways that allow for immune escape, the lack of direct Akt/mTOR pathway inhibitors must be noted in subsequent studies. This evidence concerns the gene MTOR and glioblastoma.